A Randomized, Open Label, Single-center, Single-dose, Four-period Crossover Clinical Trial to Assess the PK Profile and Safety of Budesonide Inhalation Solution AQ001S Compared to Budesonide Inhalation Suspension in Healthy Volunteers
Latest Information Update: 23 Feb 2022
At a glance
- Drugs Budesonide (Primary) ; Budesonide
- Indications SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Pharmacokinetics
- Acronyms BORA
- Sponsors Aquilon Pharma
- 21 Feb 2022 Status changed from recruiting to completed.
- 14 Dec 2021 New trial record